REDWOOD CITY, Calif. (AP) — OncoMed Pharmaceuticals Inc. (OMED) on Thursday reported fourth-quarter net income of $9.5 million, after reporting a loss in the same period a year earlier.

The Redwood City, California-based company said it had profit of 25 cents per share.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 31 cents per share.

The cancer therapy developer posted revenue of $20.6 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $5.1 million.

For the year, the company reported that its loss narrowed to $39.1 million, or $1.04 per share. Revenue was reported as $38.2 million.

In the final minutes of trading on Thursday, the company's shares hit $2.89. A year ago, they were trading at $9.14.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on OMED at

Automated Insights

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.